Positive Results, Exclusive Agreements, and Orphan Drug Designations - Research Report on Bristol-Myers Squibb, Illumina,

    Positive Results, Exclusive Agreements, and Orphan Drug Designations -
 Research Report on Bristol-Myers Squibb, Illumina, Alexion, Health Net, and
                                   Emeritus

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, July 8, 2013

NEW YORK, July 8, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting
Bristol-Myers Squibb Company (NYSE: BMY), Illumina, Inc. (NASDAQ: ILMN),
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Health Net, Inc. (NYSE: HNT),
and Emeritus Corporation (NYSE: ESC). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Bristol-Myers Squibb Company Research Report

On June 30, 2013, Bristol-Myers Squibb Company (Bristol-Myers Squibb) and
Pfizer Inc. (Pfizer) jointly announced the results of the six month Phase 3
AMPLIFY trial of 5,395 patients with acute venous thromboembolism (VTE), which
includes symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism
(PE). The Companies reported that Eliquis as a single-agent achieved the
primary efficacy endpoint of noninferiority to current standard of care
(initial parenteral enoxaparin treatment overlapped with warfarin therapy) in
the reduction of the composite endpoint of recurrent symptomatic VTE or
VTE-related death. Both the Companies now plan to initiate regulatory filings
for the initial and long-term treatment of VTE, and for extended prevention of
recurrent VTE. The Full Research Report on Bristol-Myers Squibb Company -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/88a2_BMY]

--

Illumina, Inc. Research Report

On July 1, 2013, Illumina, Inc. (Illumina) announced that Teva Pharmaceutical
Industries Ltd. (Teva) has signed an exclusive agreement with Verinata Health
(Verinata), a wholly-owned subsidiary of Illumina, for the commercialization
of the verifi non-invasive prenatal test in Israel. Under the terms of the
five-year agreement, Teva will be the exclusive distributor of the verifi
prenatal test in Israel, and all tests will be run in Verinata's
CLIA-certified (Clinical Laboratory Improvement Amendments) laboratory in
California. According to Illumina, the MOR Institute for Medical Data Ltd.
(MOR Institute), through its relationship with Teva, will provide the verifi
prenatal test to customers of Clalit Health Services who are at high risk of
having a fetus with chromosomal abnormality. Illumina also reported that MOR
Institute, which is a wholly-owned subsidiary of Clalit Health Services, will
also establish a 9000-patient clinical outcomes registry to collect
performance data and will share it with Verinata. Clalit Health Services will
reimburse for the verifi prenatal test through supplemental insurance. The
Full Research Report on Illumina, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.wsreports.com/r/full_research_report/3af7_ILMN]

--

Alexion Pharmaceuticals, Inc. Research Report

On June 27, 2013, Alexion Pharmaceuticals, Inc. (Alexion) announced that
Soliris (eculizumab), the Company's first-in-class terminal complement
inhibitor, has been granted an orphan drug designation by the US Food and Drug
Administration (FDA) for the treatment of neuromyelitis optica (NMO) - a
life-threatening, ultra-rare neurological disorder. Martin Mackay, Ph.D., EVP
and Global Head of R&D at Alexion, said, "This orphan drug designation is a
positive step toward understanding and meeting the needs of this underserved
patient population. In clinical trials to date, terminal complement inhibition
with Soliris appeared to significantly reduce the attack rate in patients with
severe, refractory relapsing NMO." According to Alexion, the Orphan drug
designation provides a drug developer with certain benefits and incentives
(including a period of marketing exclusivity) if regulatory approval is
received for the designated indication. The Full Research Report on Alexion
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/451f_ALXN]

--

Health Net, Inc. Research Report

On July 2, 2013, Health Net of California, Inc., a wholly-owned subsidiary of
Health Net, Inc. (Health Net), announced that on May 3, 2013, the Company
became aware that California member identification cards of some of the
members were inadvertently mailed to their former addresses in April and May
2013. According to the Company, the mailing was part of a program transition
of Health Net members to the Health Net Medi-Cal program, and the Company has
been investigating the issue as well as working with the California Department
of Health Care Services (DHCS) on this matter. The Company also informed that
the programming issue responsible for this action has been addressed, and
confirmed that it is in the process of notifying affected members that the
information sent to their former addresses included their plan identification
number. Health Net also reported that it has notified the appropriate
governmental authorities within the required time frames. The Full Research
Report on Health Net, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/6f92_HNT]

--

Emeritus Corporation Research Report

On June 27, 2013, Emeritus Corporation (Emeritus) announced that it has
entered into definitive agreements with Health Care REIT, Inc. (HCN) and
Merill Gardens. Under the agreements, the Company will lease a total of 38
senior housing communities in eight states, representing approximately 4,400
units, which are currently owned by a joint venture comprised of HCN and
Merill Gardens. Upon consummation of the transaction, HCN will acquire Merill
Gardens' 20% equity interest in the property and Emeritus will operate it
under a long-term triple-net master lease. Rent for the first year will be $54
million and will increase each year in the manner specified in the lease. The
initial term of the lease will be 15 years, along with an option with Emeritus
to extend it for an additional term of 15 years. The transaction, subject to
customary closing conditions, is expected to close in beginning of August
2013. The Full Research Report on Emeritus Corporation - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.wsreports.com/r/full_research_report/df13_ESC]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.